Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort study

作者：Igor Gomez-Randulfe, Federico Monaca, Ornella Cantale, Maria Lucia Reale, Loredana Mrak, Lodovica Zullo, Sofía Silva Díaz, Marta Zaragoza Bueno, Marta Moreno, Charlotte Davis, Samantha Cox, Daniel Lee, Riyaz Shah, Tom Geldart, Javier Baena, José Carlos Benítez, M.R. García Campelo, Jordi Remón, David Planchard, Domenico Galetta, Marcello Tiseo, Diego Cortinovis, Giulio Metro, Emilio Bria, Francesco Passiglia, Silvia Novello, Raffaele Califano · 发表于：Lung Cancer · 年份：2025 · DOI：10.1016/j.lungcan.2025.108797 · 被引用次数：1 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment